Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium nitrate - Genta

Drug Profile

Gallium nitrate - Genta

Alternative Names: Calstat; G 4544; G4544a; Ganite; NSC 15200

Latest Information Update: 11 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Developer Cystic Fibrosis Foundation; Emisphere Technologies; Genta (CEASED); University of Washington
  • Class Antihypercalcaemics; Antineoplastics; Calcium regulators; Heavy metals; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Malignant hypercalcaemia
  • Discontinued Bone cancer; Infections; Non-Hodgkin's lymphoma; Osteitis deformans; Osteoporosis

Most Recent Events

  • 21 Apr 2010 Pharmacokinetics data from a preliminary clinical trial in Cystic-fibrosis associated respiratory tract infections released by Genta
  • 13 Jan 2010 Preclinical pharmacodynamics data in Osteoporosis released by Genta
  • 03 Jun 2008 Interim pharmacokinetics data from a phase I trial presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top